1-3 of 3
Jutta Deckert, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Coltuximab Ravtansine (SAR3419) Demonstrates Enhanced Activity in Combination with Bendamustine, Gemcitabine and Novel Targeted Agents Such As PI3K Inhibitors in Pre-Clinical Models of Relapsed and/or Refractory Non-Hodgkins Lymphoma (NHL)

Callum M Sloss, PhD, Katie O'Callaghan, PhD, Jutta Deckert, PhD, Jenny Tsui, BS, Leanne Lanieri, BS, Angela Romanelli, PhD
Journal: Blood
Blood (2015) 126 (23): 5125.
https://doi.org/10.1182/blood.V126.23.5125.5125
Published: 2015
Journal Articles

IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models

Jutta Deckert, PhD, Callum M Sloss, PhD, Katie O'Callaghan, PhD, Jenny Tsui, BS, Nemisha Dawra, BS, Yong Yi, MD, Jennifer A Coccia, BS, Leanne Lanieri, BS, Sharon Chicklas, BS, Angela Romanelli, PhD
Journal: Blood
Blood (2015) 126 (23): 1548.
https://doi.org/10.1182/blood.V126.23.1548.1548
Published: 2015
Journal Articles

Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion By IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC)

Jutta Deckert, PhD, Jose F. Ponte, PhD, Jennifer A. Coccia, Leanne Lanieri, Sharon Chicklas, Yong Yi, Krystal Watkins, Rodrigo Ruiz-Soto, MD MSc, Angela Romanelli, PhD, Robert J. Lutz, PhD
Journal: Blood
Blood (2014) 124 (21): 3119.
https://doi.org/10.1182/blood.V124.21.3119.3119
Published: 2014